Genzyme today announced that the U.S. Food and Drug Administration has granted marketing approval for Renvela™ (sevelamer carbonate) for the control of serum phosphorus in patients with chronic ...

Sevelamer carbonate 0.8g, 2.4g; per packet; pwd for oral susp. Supplied as opaque, foil-lined, heat-sealed, packets containing 0.8 g or 2.4 g of sevelamer carbonate on an anhydrous basis. 1 Box of ...

Sevelamer carbonate 800 mg; tabs. Patients with CKD can develop hyperphosphatemia as a result of retained phosphorus, which may lead to ectopic calcification. Hyperphosphatemia plays a role in the ...

Overview: Sevelamer is taken to lower phosphate levels in your blood if you have kidney problems. Common side effects include nausea, vomiting, diarrhea, constipation, upset stomach or stomach pain, ...

Genzyme Corporation (Nasdaq: GENZ) today announced that the European Commission has approved Renvela® (sevelamer carbonate) for the control of serum phosphorus in patients with chronic kidney disease ...

Use of sevelamer was associated with a 14% decreased risk of death compared with non-use. Hemodialysis (HD) patients with hyperphosphatemia who receive sevelamer as an adjunct to calcium-based ...

Learn everything you need to know about Sevelamer-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Sevelamer is a phosphate-binding agent, prescribed for hyperphophataemia. Sevelamer can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a ...

Calcium-based phosphate binders might contribute to vascular calcification in patients receiving hemodialysis. The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (K/DOQI) ...